Clinical Trials
50 trialsWTX-212C-IIT
Zhejiang Provincial People's Hospital
IMMUNONET
Centre Leon Berard
Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors
Peking University Shenzhen Hospital
Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors
The First Affiliated Hospital of Xiamen University
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
Xinqiao Hospital of Chongqing
Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
The Affiliated Hospital of Xuzhou Medical University
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
Mainline Biosciences (Shanghai) Co., Ltd
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors
The First Hospital of Jilin University
A First-in-Human Study of PRL3-ZUMAB
National University Hospital, Singapore
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18)
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
Providence Health & Services
Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors
Fudan University
GUARDIAN
Tianjin Medical University Cancer Institute and Hospital
SINGULARITY
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
CD (Suzhou) Biopharma Co., Ltd.
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
Swiss Cancer Institute
A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
Nanfang Hospital, Southern Medical University
A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
Zhejiang University
IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors
Fudan University
A Phase I Study of JS108 in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors
University of Pittsburgh
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors
Wuxi People's Hospital
Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients With Advanced Solid Tumors
Prince of Songkla University
Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors
Hubei Biological Medicine Industrial Technology Institute Co., Ltd.
Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
Fox Chase Cancer Center
A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors
Chinese PLA General Hospital
CHITIN
Herlev Hospital
Study of Apatinib and MASCT in Patients With Advanced Solid Tumors
The First People's Hospital of Lianyungang
Lapatinib and Bortezomib in Patients With Advanced Malignancies
Georgetown University
Sorafenib Plus S-1 in Advanced Solid Tumors
National Health Research Institutes, Taiwan
A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Ixabepilone and Pemetrexed/Solid Tumors
University of Southern California
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
Georgetown University
A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours
National University Hospital, Singapore
BEL
Duke University
A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors
Dartmouth-Hitchcock Medical Center
Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors
Southern Europe New Drug Organization
Lenalidomide and Paclitaxel in Advanced Solid Tumors
Southern Europe New Drug Organization
LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors
Southern Europe New Drug Organization
Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets
Southern Europe New Drug Organization
Satraplatin and Vinorelbine in Advanced Solid Tumors
Southern Europe New Drug Organization